Literature DB >> 21900154

Discovery and validation of serum protein changes in type 1 diabetes patients using high throughput two dimensional liquid chromatography-mass spectrometry and immunoassays.

Wenbo Zhi1, Ashok Sharma, Sharad Purohit, Eric Miller, Bruce Bode, Stephen W Anderson, John Chip Reed, R Dennis Steed, Leigh Steed, Diane Hopkins, Jin-Xiong She.   

Abstract

Type 1 diabetes (T1D) is expected to cause significant changes in the serum proteome; however, few studies have systematically assessed the proteomic profile change associated with the disease. In this study, a semiquantitative spectral counting-based two dimensional liquid chromatography mass spectrometry platform was used to analyze serum samples from T1D patients and controls. In this discovery phase, significant differences were found for 21 serum proteins implicated in inflammation, oxidation, metabolic regulation, and autoimmunity. To assess the validity of these findings, six candidate proteins including adiponectin, insulin-like growth factor binding protein 2, serum amyloid protein A, C-reactive protein, myeloperoxidase, and transforming growth factor beta induced were selected for subsequent immune assays for 1139 T1D patients and 848 controls. A series of statistical analyses using cases and controls matched for age, sex, and genetic risk confirmed that T1D patients have significantly higher serum levels for four of the six proteins: adiponectin (odds ratio (OR) = 1.95, p = 10(-27)), insulin-like growth factor binding protein 2 (OR = 2.02, p < 10(-20)), C-reactive protein (OR = 1.13, p = 0.007), serum amyloid protein A (OR = 1.51, p < 10(-16)); whereas the serum levels were significantly lower in patients than controls for the two other proteins: transforming growth factor beta induced (OR = 0.74, p < 10(-5)) and myeloperoxidase (OR = 0.51, p < 10(-41)). Compared with subjects in the bottom quartile, subjects in the top quartile for adiponectin (OR = 6.29, p < 10(-37)), insulin-like growth factor binding protein 2 (OR = 7.95, p < 10(-46)), C-reactive protein (OR = 1.38, p = 0.025), serum amyloid protein A (OR = 3.36, p < 10(-16)) had the highest risk of T1D, whereas subjects in the top quartile of transforming growth factor beta induced (OR = 0.41, p < 10(-11)) and myeloperoxidase (OR = 0.10, p < 10(-43)) had the lowest risk of T1D. These findings provided valuable information on the proteomic changes in the sera of T1D patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21900154      PMCID: PMC3226412          DOI: 10.1074/mcp.M111.012203

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  48 in total

Review 1.  TGFBIp/betaig-h3 protein: a versatile matrix molecule induced by TGF-beta.

Authors:  Narendra Thapa; Byung-Heon Lee; In-San Kim
Journal:  Int J Biochem Cell Biol       Date:  2007-06-24       Impact factor: 5.085

2.  Combinatorial hexapeptide ligand libraries (ProteoMiner): an innovative fractionation tool for differential quantitative clinical proteomics.

Authors:  Sonja Hartwig; Akos Czibere; Jorg Kotzka; Waltraud Passlack; Rainer Haas; Jürgen Eckel; Stefan Lehr
Journal:  Arch Physiol Biochem       Date:  2009-07       Impact factor: 4.076

3.  Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity.

Authors:  Y Arita; S Kihara; N Ouchi; M Takahashi; K Maeda; J Miyagawa; K Hotta; I Shimomura; T Nakamura; K Miyaoka; H Kuriyama; M Nishida; S Yamashita; K Okubo; K Matsubara; M Muraguchi; Y Ohmoto; T Funahashi; Y Matsuzawa
Journal:  Biochem Biophys Res Commun       Date:  1999-04-02       Impact factor: 3.575

4.  Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes.

Authors:  Mathias Fasshauer; Johannes Klein; Susanne Neumann; Markus Eszlinger; Ralf Paschke
Journal:  Biochem Biophys Res Commun       Date:  2002-01-25       Impact factor: 3.575

5.  Regulation of binding proteins for insulin-like growth factors (IGF) in humans. Increased expression of IGF binding protein 2 during IGF I treatment of healthy adults and in patients with extrapancreatic tumor hypoglycemia.

Authors:  J Zapf; C Schmid; H P Guler; M Waldvogel; C Hauri; E Futo; P Hossenlopp; M Binoux; E R Froesch
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

6.  Changes in superoxide dismutase activities and concentrations and myeloperoxidase activities in leukocytes from patients with diabetes mellitus.

Authors:  K Uchimura; A Nagasaka; R Hayashi; M Makino; M Nagata; H Kakizawa; T Kobayashi; K Fujiwara; T Kato; K Iwase; R Shinohara; K Kato; M Itoh
Journal:  J Diabetes Complications       Date:  1999 Sep-Dec       Impact factor: 2.852

7.  Determinants of serum adiponectin in persons with and without type 1 diabetes.

Authors:  David M Maahs; Lorraine G Ogden; Janet K Snell-Bergeon; Gregory L Kinney; R Paul Wadwa; John E Hokanson; Dana Dabelea; Adam Kretowski; Robert H Eckel; Marian Rewers
Journal:  Am J Epidemiol       Date:  2007-06-24       Impact factor: 4.897

8.  Elevation of urinary betaig-h3, transforming growth factor-beta-induced protein in patients with type 2 diabetes and nephropathy.

Authors:  Sung-Woo Ha; Hyun-Ji Kim; Jong-Sup Bae; Gui-Hwa Jeong; Sung-Chang Chung; Jung-Guk Kim; Sun-Hee Park; Yong-Lim Kim; Sin Kam; In-San Kim; Bo-Wan Kim
Journal:  Diabetes Res Clin Pract       Date:  2004-08       Impact factor: 5.602

9.  Insulin-like growth factor (IGF)-I and -II and IGF-binding proteins-1, -2, and -3 in children and adolescents with diabetes mellitus: correlation with metabolic control and height attainment.

Authors:  B Strasser-Vogel; W F Blum; R Past; U Kessler; A Hoeflich; B Meiler; W Kiess
Journal:  J Clin Endocrinol Metab       Date:  1995-04       Impact factor: 5.958

10.  Use of insulin-like growth factor-binding protein-2 (IGFBP-2), IGFBP-3, and IGF-I for assessing growth hormone status in short children.

Authors:  W J Smith; T J Nam; L E Underwood; W H Busby; A Celnicker; D R Clemmons
Journal:  J Clin Endocrinol Metab       Date:  1993-11       Impact factor: 5.958

View more
  24 in total

1.  The role of proteomics in assessing beta-cell dysfunction and death in type 1 diabetes.

Authors:  Ernesto S Nakayasu; Wei-Jun Qian; Carmella Evans-Molina; Raghavendra G Mirmira; Decio L Eizirik; Thomas O Metz
Journal:  Expert Rev Proteomics       Date:  2019-06-24       Impact factor: 3.940

Review 2.  Novel biomarkers in type 1 diabetes.

Authors:  Yulan Jin; Jin-Xiong She
Journal:  Rev Diabet Stud       Date:  2012-12-28

3.  Peptide serum markers in islet autoantibody-positive children.

Authors:  Christine von Toerne; Michael Laimighofer; Peter Achenbach; Andreas Beyerlein; Tonia de Las Heras Gala; Jan Krumsiek; Fabian J Theis; Anette G Ziegler; Stefanie M Hauck
Journal:  Diabetologia       Date:  2016-11-04       Impact factor: 10.122

4.  Longitudinal proteomics analysis in the immediate microenvironment of islet allografts during progression of rejection.

Authors:  Oscar Alcazar; Luis F Hernandez; Ernesto S Nakayasu; Paul D Piehowski; Charles Ansong; Midhat H Abdulreda; Peter Buchwald
Journal:  J Proteomics       Date:  2020-05-20       Impact factor: 4.044

Review 5.  Early life origin of type 1 diabetes.

Authors:  Mikael Knip; Kristiina Luopajärvi; Taina Härkönen
Journal:  Semin Immunopathol       Date:  2017-11-23       Impact factor: 9.623

Review 6.  Serum biomarkers for diagnosis and prediction of type 1 diabetes.

Authors:  Lian Yi; Adam C Swensen; Wei-Jun Qian
Journal:  Transl Res       Date:  2018-08-01       Impact factor: 7.012

7.  Serum insulin-like growth factor binding protein 6 (IGFBP6) is increased in patients with type 1 diabetes and its complications.

Authors:  Shangsu Lu; Sharad Purohit; Ashok Sharma; Wenbo Zhi; Mingfang He; Yiqian Wang; Chao-Jun Li; Jin-Xiong She
Journal:  Int J Clin Exp Med       Date:  2012-06-10

8.  Type 1 diabetes cadaveric human pancreata exhibit a unique exocrine tissue proteomic profile.

Authors:  Chih-Wei Liu; Mark A Atkinson; Qibin Zhang
Journal:  Proteomics       Date:  2016-04-13       Impact factor: 3.984

9.  Temporal expression profiling of plasma proteins reveals oxidative stress in early stages of Type 1 Diabetes progression.

Authors:  Chih-Wei Liu; Lisa Bramer; Bobbie-Jo Webb-Robertson; Kathleen Waugh; Marian J Rewers; Qibin Zhang
Journal:  J Proteomics       Date:  2017-10-07       Impact factor: 4.044

10.  Immunological biomarkers: catalysts for translational advances in autoimmune diabetes.

Authors:  S T Ahmed; E Akirav; E Bradshaw; J Buckner; E McKinney; F J Quintana; F Waldron-Lynch; J Nepom
Journal:  Clin Exp Immunol       Date:  2013-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.